KRAS and colorectal carcinoma: Porrud et al. studied KRAS wild-type and mutant colorectal cancer cells (CRC) and cancer stem cells (CSCs), showing that 5-Fu can induce CRC apoptotic cell damage but upregulate CSCs autophagy, leading to drug resistance, but inhibition of this autophagy using 5-FU in combination with cetuximab, an anti-EGFR monoclonal antibody, increased the response of cancer stem cells to therapy [46].